OCT 29 2026
Gilead Sciences — bictegravir/lenacapavir $GILD
for HIV-1 infection (treatment)
Accepted APR 29 2026.
About
HIV-1 is a virus that attacks the immune system, weakening the body’s ability to fight infections and leading to chronic illness if untreated. Bictegravir/lenacapavir combines two drugs: bictegravir blocks a key enzyme HIV uses to replicate its genetic material, while lenacapavir disrupts the virus’s protective protein shell. Together, they may offer a simplified treatment option that targets HIV at multiple stages of its lifecycle, potentially helping patients maintain viral suppression with fewer doses.
Pivotal trial
The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with human immunodeficiency virus (PWH) who are virologically suppressed (HIV-1 RNA levels \< 50 copies/mL) on B/F/TAF for ≥ 6 months prior to screening. The primary objective is to evaluate the efficacy of switching to oral weekly ISL/...
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on bictegravir/lenacapavir
- TheBodyPro: Can two-drug therapy benefit older, HIV treatment-experienced patients? The promise of bictegravir/lenacapavir - European AIDS Treatment Group
- Results Show Single-Tablet Regimen of Bictegravir/Lenacapavir Maintains Virological Suppression of HIV - Drug Topics
- Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens - Aidsmap
- [CROI 2026] aidsmap: Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens - European AIDS Treatment Group
- Bictegravir/Lenacapavir Combo Pill Could Replace Complex HIV Treatment - poz.com